 First multiple-dose psilocybin clinical trial will be conducted at Braxia Healths Canadian Rapid Treatment Centers Trial will include adults with treatment-resistant depression and will also enroll adults who have previously tried electroconvulsive therapy andor intravenous ketamine TORONTO, Aug. 27, 2021 PRNewswire - Braxia Scientific Corp. Braxia Scientific, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce Braxia Scientifics clinical research and development team will commence a randomized clinical trial RCT using psilocybin. This will be the broadest study of its kind, said Dr. Joshua Rosenblat, the trials principal investigator and medical director of the Canadian Rapid Treatment Centre of Excellence Inc. CRTCE, a wholly owned subsidiary of Braxia Scientific. 